Literature DB >> 28674674

Targeting the Immune System with Pharmacotherapy in Schizophrenia.

Jennifer K Melbourne1, Benjamin Feiner1, Cherise Rosen1, Rajiv P Sharma1,2.   

Abstract

Entities:  

Keywords:  anti-inflammatory; antipsychotics; cytokines; drugs; immune; schizophrenia

Year:  2017        PMID： 28674674      PMCID： PMC5493152          DOI： 10.1007/s40501-017-0114-0

Source DB:  PubMed          Journal:  Curr Treat Options Psychiatry


× No keyword cloud information.
  94 in total

1.  The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma.

Authors:  Qian Bian; Takahiro Kato; Akira Monji; Sadayuki Hashioka; Yoshito Mizoguchi; Hideki Horikawa; Shigenobu Kanba
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-05       Impact factor: 5.067

Review 2.  A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness.

Authors:  Michael Maes; Piotr Galecki; Yong Seun Chang; Michael Berk
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-05-12       Impact factor: 5.067

Review 3.  Methotrexate--how does it really work?

Authors:  Edwin S L Chan; Bruce N Cronstein
Journal:  Nat Rev Rheumatol       Date:  2010-03       Impact factor: 20.543

Review 4.  Adaptive Immunity in Schizophrenia: Functional Implications of T Cells in the Etiology, Course and Treatment.

Authors:  Monojit Debnath
Journal:  J Neuroimmune Pharmacol       Date:  2015-07-11       Impact factor: 4.147

5.  Adjunctive minocycline for schizophrenia: A meta-analysis of randomized controlled trials.

Authors:  Ying-Qiang Xiang; Wei Zheng; Shi-Bin Wang; Xin-Hu Yang; Dong-Bin Cai; Chee H Ng; Gabor S Ungvari; Deanna L Kelly; Wei-Ying Xu; Yu-Tao Xiang
Journal:  Eur Neuropsychopharmacol       Date:  2016-12-02       Impact factor: 4.600

6.  Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Authors:  G Paul Amminger; Miriam R Schäfer; Konstantinos Papageorgiou; Claudia M Klier; Sue M Cotton; Susan M Harrigan; Andrew Mackinnon; Patrick D McGorry; Gregor E Berger
Journal:  Arch Gen Psychiatry       Date:  2010-02

Review 7.  Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Kazuto Oya; Taro Kishi; Nakao Iwata
Journal:  Hum Psychopharmacol       Date:  2014-09       Impact factor: 1.672

8.  Simvastatin augmentation for recent-onset psychotic disorder: A study protocol.

Authors:  Marieke J H Begemann; Maya J L Schutte; Margot I E Slot; Janine Doorduin; P Roberto Bakker; Neeltje E M van Haren; Iris E C Sommer
Journal:  BBA Clin       Date:  2015-07-03

Review 9.  Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness.

Authors:  Michael Berk; Olivia Dean; Hemmo Drexhage; John J McNeil; Steven Moylan; Adrienne O'Neil; Christopher G Davey; Livia Sanna; Michael Maes
Journal:  BMC Med       Date:  2013-03-18       Impact factor: 8.775

Review 10.  Allopregnanolone and neuroinflammation: a focus on multiple sclerosis.

Authors:  Farshid Noorbakhsh; Glen B Baker; Christopher Power
Journal:  Front Cell Neurosci       Date:  2014-06-03       Impact factor: 5.505
View more
  3 in total

Review 1.  The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment.

Authors:  Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey
Journal:  Biomed Pharmacother       Date:  2021-01-01       Impact factor: 6.529

Review 2.  Cytokine Imbalance as a Biomarker of Treatment-Resistant Schizophrenia.

Authors:  Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Mustafa Al-Zamil; Andrey P Otmakhov; Nikolay G Neznanov; German A Shipulin; Marina M Petrova; Natalia P Garganeeva; Regina F Nasyrova
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

3.  Treatment with the antipsychotic risperidone is associated with increased M1-like JAK-STAT1 signature gene expression in PBMCs from participants with psychosis and THP-1 monocytes and macrophages.

Authors:  Jennifer K Melbourne; Yanzhen Pang; Mi Rae Park; Niyati Sudhalkar; Cherise Rosen; Rajiv P Sharma
Journal:  Int Immunopharmacol       Date:  2019-12-25       Impact factor: 4.932
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.